Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$38.96 - $42.75 $2,337 - $2,565
60 Added 9.13%
717 $29,000
Q1 2024

May 01, 2024

BUY
$40.88 - $43.27 $2,330 - $2,466
57 Added 9.5%
657 $27,000
Q4 2023

Jan 25, 2024

BUY
$20.27 - $42.44 $405 - $848
20 Added 3.45%
600 $25,000
Q3 2023

Nov 02, 2023

SELL
$20.26 - $31.91 $22,691 - $35,739
-1,120 Reduced 65.88%
580 $12,000
Q2 2023

Aug 11, 2023

BUY
$23.9 - $35.38 $6,692 - $9,906
280 Added 19.72%
1,700 $54,000
Q3 2022

Nov 07, 2022

BUY
$25.5 - $41.42 $1,020 - $1,656
40 Added 2.9%
1,420 $40,000
Q2 2022

Aug 03, 2022

BUY
$20.62 - $37.15 $9,072 - $16,346
440 Added 46.81%
1,380 $36,000
Q1 2022

Apr 29, 2022

SELL
$23.5 - $35.38 $29,516 - $44,437
-1,256 Reduced 57.19%
940 $33,000
Q4 2021

Feb 03, 2022

BUY
$29.21 - $44.64 $64,145 - $98,029
2,196 New
2,196 $57,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.